MORRIS PLAINS, N.J., May 2, 2011 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that a single dose of clivatuzumab tetraxetan labeled with the potent therapeutic radioisotope, yttrium-90 (90Y), produced transient partial responses in some patients with advanced pancreatic cancer and the treatment was well tolerated with manageable hematological toxicity at the maximum tolerated 90Y dose.
